CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54

BlueReg Group

About BlueReg Group

EXPERTISE, FLEXIBILITY, CUSTOMER ORIENTATED are our DNA

Drug Development : We will provide you with an end-to-end project plan to guide you from the development of your product right through to authorisation and beyond.
CMC activities can be fully managed by our team: coordination of all activities in pharmaceutical development from API selec

...

Sales Markets

Africa
Central America (e.g. Mexico)
East Asia (e.g. China, Japan, Korea)
Europe - EU countries
Europe - non EU (e.g. UK, Russia, ex-CIS countries)
Middle East Region (e.g. UAE)
North America (USA, Canada)
Oceania
South America (e.g. Brazil, Colombia)
South Asia (e.g. India, Pakistan, Sri Lanka)
South East Asia (e.g. Thailand, Philippines, Singapore)

Categories

Contract Services - Contract Services Regulatory Affairs

FR
2019

On CPHI since

Compare

Add to favorites Added to favorites

Contact info

+33 (0)4 22 00 01 00
Website
1800 route des crêtes Les Deux Arcs - Bât A, Sophia Antipolis, 06560, Paris, France

Products from BlueReg Group (1)

Product CMC Services - Chemistry, Manufacturing and Controls

BlueReg has a dedicated team of CMC consultants with significant expertise in all areas of CMC development.

Our experts can advise you on pharmaceutical development strategy and provide oversight for the overall product development process to ensure key development milestones are successfully re...

Compare

BlueReg Group Resources (1)

Brochure Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France

In the context of PRIME, a European biotechnological company entrusted BlueReg CMC team with the task of bringing the available quality data package of a synthetic peptide to global registration prerequisites for the next steps of development (the Compassionate use program in France, Phase III global program, registration in Europe and US) and to write the Quality part of the IMPD for early access submission in France.